Skip to content
Article Rich – Lifestyle
Author:
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals Announces First Patient Dosed in Pivotal Global Phase 3 NORTHSTAR Study of Oral Gildeuretinol in Stargardt Disease
June 8, 2026
Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
April 30, 2026